Antibody Pair Development

A capture reagent retains the analyte and a detection reagent measures the captured material. Both must bind at the same time without unacceptable competition or steric interference. Pair suitability is demonstrated in the assay, rather than inferred from two individual datasheets.

Yes, both sides of the assay can be included in the project specification. If you already have a suitable capture or detection reagent, include its clone, format, amount and available data so the missing component and pairing work can be assessed.

No, antigen production can be discussed as a project stage. If you have material available, provide identity, purity, concentration, buffer and storage information. Its suitability depends on how closely it represents the target recognised in the intended assay.

Compare the full work package: antigen preparation, number and type of candidates, screening conditions, matrix testing, validation endpoints, final material and documentation. Clarify the milestones and what happens if agreed criteria are not met. A low entry price does not describe the total development cost.

Allow approximately 5–8 months for a full development programme as an initial planning guide. An existing reagent starting point may change the route. ABMIUM confirms an indicative schedule after technical review, including dependencies such as antigen readiness and access to representative samples.

Yes. Describe the target structure, relevant modifications, species and sample context. Native epitope accessibility, antigen quality and discrimination from related molecules need particular attention. Feasibility and the proposed strategy are reviewed before work is commissioned.

Select the studies required for your decision: calibration curves, sensitivity, precision, working range, specificity and matrix performance. Affinity, epitope binning, stability and lot comparability can be discussed as additional work. Each result should be accompanied by the method and conditions used.

Supply planning can be discussed during scoping, including required annual quantities, formulation, repeat production and release testing. Agree access to clones or sequences, ownership, licensing and manufacturing documentation explicitly rather than assuming these are included.

Review the evidence against the agreed criteria before deciding on further work. Options may include different antigen material, additional candidates or revised assay conditions. Subsequent stages, costs and decision points require agreement; successful pair discovery is not guaranteed for every target.

The service is offered for Research Use Only. A diagnostic intended use requires a separately agreed development, quality and regulatory programme. Research pairing results alone do not establish that an assay is cleared or suitable for clinical decisions.

Pair development focuses on compatible capture and detection reagents. A complete ELISA programme can also include coating, detection chemistry, matrix optimisation, calibration, controls and a finished assay configuration. Agree where your project should stop so you receive the evidence and material needed for the next stage.

Not necessarily. Western blot binding may involve a denatured target, while a sandwich assay may require simultaneous recognition of accessible epitopes on the target in solution. Assess pairing experimentally using suitable antigen and relevant assay conditions.

Pricing depends on antigen readiness, antibody generation, candidate-screening depth, matrix testing and validation scope. ABMIUM provides a project-specific quotation after reviewing the requirement. Ask for a breakdown of stages, deliverables, optional studies and further-work decision points so you can compare the total scope rather than an entry price alone.